Solid Biosciences (SLDB) Competitors $6.83 -0.01 (-0.15%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$6.64 -0.19 (-2.71%) As of 08/1/2025 06:33 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock SLDB vs. HRMY, DNLI, CNTA, VCEL, CGON, BLTE, KNSA, OCUL, APGE, and ARQTShould you be buying Solid Biosciences stock or one of its competitors? The main competitors of Solid Biosciences include Harmony Biosciences (HRMY), Denali Therapeutics (DNLI), Centessa Pharmaceuticals (CNTA), Vericel (VCEL), CG Oncology (CGON), Belite Bio (BLTE), Kiniksa Pharmaceuticals International (KNSA), Ocular Therapeutix (OCUL), Apogee Therapeutics (APGE), and Arcutis Biotherapeutics (ARQT). These companies are all part of the "pharmaceutical products" industry. Solid Biosciences vs. Its Competitors Harmony Biosciences Denali Therapeutics Centessa Pharmaceuticals Vericel CG Oncology Belite Bio Kiniksa Pharmaceuticals International Ocular Therapeutix Apogee Therapeutics Arcutis Biotherapeutics Harmony Biosciences (NASDAQ:HRMY) and Solid Biosciences (NASDAQ:SLDB) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, profitability, valuation, media sentiment, earnings, dividends and risk. Do insiders and institutionals believe in HRMY or SLDB? 86.2% of Harmony Biosciences shares are owned by institutional investors. Comparatively, 81.5% of Solid Biosciences shares are owned by institutional investors. 23.6% of Harmony Biosciences shares are owned by company insiders. Comparatively, 1.9% of Solid Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Which has more volatility & risk, HRMY or SLDB? Harmony Biosciences has a beta of 0.84, meaning that its stock price is 16% less volatile than the S&P 500. Comparatively, Solid Biosciences has a beta of 2.43, meaning that its stock price is 143% more volatile than the S&P 500. Which has preferable valuation and earnings, HRMY or SLDB? Harmony Biosciences has higher revenue and earnings than Solid Biosciences. Solid Biosciences is trading at a lower price-to-earnings ratio than Harmony Biosciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioHarmony Biosciences$714.73M2.76$145.49M$2.6213.13Solid Biosciences$8.09M65.44-$124.70M-$2.99-2.28 Is HRMY or SLDB more profitable? Harmony Biosciences has a net margin of 20.53% compared to Solid Biosciences' net margin of 0.00%. Harmony Biosciences' return on equity of 24.32% beat Solid Biosciences' return on equity.Company Net Margins Return on Equity Return on Assets Harmony Biosciences20.53% 24.32% 15.92% Solid Biosciences N/A -68.15%-55.33% Does the media refer more to HRMY or SLDB? In the previous week, Harmony Biosciences had 7 more articles in the media than Solid Biosciences. MarketBeat recorded 8 mentions for Harmony Biosciences and 1 mentions for Solid Biosciences. Harmony Biosciences' average media sentiment score of 1.59 beat Solid Biosciences' score of 0.00 indicating that Harmony Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Harmony Biosciences 6 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Solid Biosciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do analysts rate HRMY or SLDB? Harmony Biosciences currently has a consensus price target of $51.00, indicating a potential upside of 48.26%. Solid Biosciences has a consensus price target of $15.10, indicating a potential upside of 121.08%. Given Solid Biosciences' stronger consensus rating and higher probable upside, analysts clearly believe Solid Biosciences is more favorable than Harmony Biosciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Harmony Biosciences 0 Sell rating(s) 1 Hold rating(s) 8 Buy rating(s) 1 Strong Buy rating(s) 3.00Solid Biosciences 0 Sell rating(s) 0 Hold rating(s) 10 Buy rating(s) 2 Strong Buy rating(s) 3.17 SummaryHarmony Biosciences beats Solid Biosciences on 11 of the 17 factors compared between the two stocks. Get Solid Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for SLDB and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding SLDB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SLDB vs. The Competition Export to ExcelMetricSolid BiosciencesMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$530.21M$3.00B$5.48B$9.51BDividend YieldN/A2.43%4.73%4.09%P/E Ratio-2.2817.6228.6723.80Price / Sales65.44179.18373.9066.58Price / CashN/A41.9535.4557.96Price / Book1.998.508.275.55Net Income-$124.70M-$55.06M$3.24B$259.03M7 Day Performance-2.43%-3.98%-3.69%-4.59%1 Month Performance40.25%9.59%4.33%4.46%1 Year Performance-12.99%6.72%25.95%18.03% Solid Biosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SLDBSolid Biosciences2.6568 of 5 stars$6.83-0.1%$15.10+121.1%-20.9%$530.21M$8.09M-2.28100Gap DownHRMYHarmony Biosciences4.7364 of 5 stars$36.73-1.3%$51.00+38.9%+5.1%$2.10B$714.73M13.98200Positive NewsUpcoming EarningsDNLIDenali Therapeutics4.5775 of 5 stars$14.23-1.7%$33.71+136.9%-42.4%$2.07B$330.53M-5.34430News CoverageUpcoming EarningsCNTACentessa Pharmaceuticals3.0332 of 5 stars$15.35-1.4%$28.10+83.1%+63.4%$2.05B$6.85M-8.48200News CoverageAnalyst ForecastInsider TradeVCELVericel2.3238 of 5 stars$39.16-3.0%$61.14+56.2%-25.0%$1.99B$238.54M1,316.47300Trending NewsEarnings ReportAnalyst ForecastShort Interest ↑Analyst RevisionCGONCG Oncology1.9207 of 5 stars$25.95-1.4%$55.30+113.1%-22.3%$1.98B$1.14M-17.2461News CoverageGap DownBLTEBelite Bio2.1471 of 5 stars$61.86-0.7%$96.67+56.3%+35.4%$1.97BN/A-45.4910News CoverageUpcoming EarningsKNSAKiniksa Pharmaceuticals International3.1509 of 5 stars$26.95-0.6%$39.67+47.2%+24.1%$1.97B$423.24M-107.82220News CoverageEarnings ReportAnalyst ForecastAnalyst RevisionOCULOcular Therapeutix3.6116 of 5 stars$11.88-0.7%$17.33+45.9%+47.7%$1.90B$63.72M-10.35230Upcoming EarningsAPGEApogee Therapeutics2.4749 of 5 stars$40.74+0.4%$99.00+143.0%-17.5%$1.87BN/A-11.3091Positive NewsARQTArcutis Biotherapeutics2.5048 of 5 stars$15.02+0.7%$18.80+25.2%+50.7%$1.79B$196.54M-14.46150News CoveragePositive NewsUpcoming Earnings Related Companies and Tools Related Companies Harmony Biosciences Competitors Denali Therapeutics Competitors Centessa Pharmaceuticals Competitors Vericel Competitors CG Oncology Competitors Belite Bio Competitors Kiniksa Pharmaceuticals International Competitors Ocular Therapeutix Competitors Apogee Therapeutics Competitors Arcutis Biotherapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SLDB) was last updated on 8/2/2025 by MarketBeat.com Staff From Our PartnersElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredChina just unlocked Nvidia’s AI chips—what that means for youTired of Missing Big AI Moves Like Nvidia? You’re not the problem—your trading system is. Tim’s XGPT system...Timothy Sykes | SponsoredThis Social Security Shift Could Boost Benefits by 400%If you currently collect Social Security—or plan to in the future—this may be one of the most important update...InvestorPlace | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredA new rule goes live in July — and the banks are quietly crushing itA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredYour blueprint for crypto wealthMark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything…Crypto 101 Media | SponsoredJeff Bezos Launches "ChatGPT Killer"?Amazon just launched Nova—its secretive new AI system designed to rival ChatGPT. Bezos says he now spends 95% ...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Solid Biosciences Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Solid Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
